ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
Dendrimers as high relaxivity MR contrast agents.
Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Applying dendrimer nanoprobes to the diagnosis and evaluation of kidney fibrosis.Nanomedicine (London, England) · 2026Review
- The potential of nanoparticle-based contrast agents in the diagnosis of neurodegenerative pathologies.Nanomedicine (London, England) · 2025Article
- Nanoparticle-Based Approaches in the Diagnosis and Treatment of Brain Tumors.Journal of clinical medicine · 2024Review
- Recent advances in nanomaterial-driven strategies for diagnosis and therapy of vascular anomalies.Journal of nanobiotechnology · 2024Review
- Dendrimers: Advancements and Potential Applications in Cancer Diagnosis and Treatment-An Overview.Pharmaceutics · 2023Review
- Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment.Frontiers in pharmacology · 2023Review
- Applications and Limitations of Dendrimers in Biomedicine.Molecules (Basel, Switzerland) · 2020Review
- Opportunities in Interventional and Diagnostic Imaging by Using High-Performance Low-Field-Strength MRI.Radiology · 2019Article
- Cytotoxicity of Dendrimers.Biomolecules · 2019Review
- A review of molecular imaging of atherosclerosis and the potential application of dendrimer in imaging of plaque.International journal of nanomedicine · 2017Review
- Dendrimer-Based Responsive MRI Contrast Agents (G1-G4) for Biosensor Imaging of Redundant Deviation in Shifts (BIRDS).Bioconjugate chemistry · 2015Article
- Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases.Advanced healthcare materials · 2015Review
- Advances in nanoprobes for molecular MRI of Alzheimer's disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
- A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.Contrast media & molecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Dendrimers are versatile macromolecules with tremendous potential as magnetic resonance imaging (MRI) contrast agents. Dendrimer-based agents provide distinct advantages over low-molecular-weight gadolinium chelates, including enhanced r1 relaxivity due to slow rotational dynamics, tunable pharmacokinetics that can be adapted for blood pool, liver, kidney, and lymphatic imaging, the ability to be a drug carrier, and flexibility for labeling due to their inherent multivalency. Clinical applications are increasingly being developed, particularly in lymphatic imaging. Herein we present a broad overview of dendrimer-based MRI contrast agents with attention to the unique chemistry and physical properties as well as emerging clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.